Aspire Biopharma (NASDAQ: ASBP) updates warrant terms after stock splits
Rhea-AI Filing Summary
Aspire Biopharma Holdings, Inc. clarified the current terms of its Nasdaq-listed public warrants, which trade under the symbol ASBPW, following requests from warrant holders. The warrants were originally issued on February 23, 2022 in connection with the initial public offering of its predecessor, Power Up Acquisition Corp.
The warrants initially had an exercise price of $11.50 per share, subject to adjustment for events such as share consolidations. After a 1-for-30 reverse stock split on January 16, 2026 and an additional 40-for-1 reverse split on May 11, 2026, each public warrant now carries an exercise price of $13,800 per share and a ratio of 1,200 warrants to purchase one share of common stock.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
New warrant exercise price: $13,800 per share
Warrant-to-share ratio: 1,200 Warrants for one share
Original warrant exercise price: $11.50 per share
+3 more
6 metrics
New warrant exercise price
$13,800 per share
Exercise price of public warrants after two reverse stock splits
Warrant-to-share ratio
1,200 Warrants for one share
Number of public warrants required to purchase one common share
Original warrant exercise price
$11.50 per share
Initial exercise price of public warrants issued February 23, 2022
Reverse stock split ratio (January 16, 2026)
1-for-30
Reverse stock split effected on January 16, 2026
Reverse stock split ratio (May 11, 2026)
40-for-1
Additional reverse split effected on May 11, 2026
Common stock par value
$0.0001 per share
Par value of Aspire Biopharma common stock listed on Nasdaq
Key Terms
public warrants, reverse stock split, exercise price, Emerging growth company, +1 more
5 terms
public warrants financial
"Pursuant to requests from holders of the Company’s public warrants"
Public warrants are tradable securities that give the holder the right to buy a company’s stock at a fixed price before a set expiration date. Like a coupon that lets you purchase shares later at a preset price, they matter to investors because using them can bring new cash into the company but also increase the total number of shares outstanding, which can dilute existing ownership and influence the stock’s price and potential gains.
reverse stock split financial
"On January 16, 2026, the Company affected a reverse stock split of 1 for 30"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
exercise price financial
"The Warrants had an initial exercise price which was $11.50 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
initial public offering financial
"issued on February 23, 2022 in connection with the initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Aspire Biopharma (ASBP) clarify about its public warrants?
Aspire Biopharma clarified the current terms of its public warrants, including the updated $13,800 exercise price and the new ratio of 1,200 warrants for one share of common stock after two reverse stock splits in 2026.
What is the new exercise price of Aspire Biopharma's ASBPW public warrants?
The ASBPW public warrants now have an exercise price of $13,800 per share. This reflects adjustments made after a 1-for-30 reverse stock split in January 2026 and a further 40-for-1 reverse split in May 2026.
Which stock splits affected Aspire Biopharma (ASBP) public warrant terms?
Aspire Biopharma’s public warrant terms were affected by a 1-for-30 reverse stock split on January 16, 2026 and an additional 40-for-1 reverse split on May 11, 2026, leading to significantly adjusted warrant pricing and ratio.
When were Aspire Biopharma (ASBP) public warrants originally issued?
The public warrants were originally issued on February 23, 2022 in connection with the initial public offering of Power Up Acquisition Corp., Aspire Biopharma’s predecessor, with an initial exercise price of $11.50 per share.
On which symbols do Aspire Biopharma (ASBP) securities trade on Nasdaq?
Aspire Biopharma’s common stock trades on Nasdaq under the symbol ASBP, and its public warrants trade under the symbol ASBPW. The common stock has a par value of $0.0001 per share.